Novo Nordisk warns on sales and operating profit:
This article was originally published in Clinica
Danish company Novo Nordisk has warned that its first-quarter sales have been lower than expected and that full-year sales are not likely to reach previously forecast levels. The company has reduced expectations for full-year operating profit growth from 15% to 5-10%. The Bagsvaerd-based company attributes the poor performance in part to the fact that sales growth of insulin products in Europe have been hit by a slower than expected conversion to analogs and new devices.